EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Going for a “KDIP” in colorectal cancer treatment

Jastrinjan Kaur, Laura Soucek

Clinical and Translational Discovery · 2022

DOI: 10.1002/ctd2.108 ↗

At a glance

Journal article in Clinical and Translational Discovery, 2022. Written by Jastrinjan Kaur and 1 co-authors. 10 references. The full text is freely available (open access, CC BY 4.0).

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Protein-protein interactions (PPIs) are the foundation of a plethora of cellular functions ranging from DNA replication to signal transduction and cell migration, processes that are often dysregulated in disease. Therefore, it is not surprising that they are much sought after targets in the treatment of diseases including cancer and infectious and neurodegenerative diseases. PPIs take place through interfaces that are large in area, relatively flat and devoid of features such as binding pockets.1 Owing to these properties, they are generally hard to target using small molecules, currently the most dominant drug type in the pharmaceutical market. Since the advent of peptide therapeutics in research as well as the market, targeting PPIs has become a more plausible approach. This is due to the fact that therapeutic peptides, in general, show superior affinity and specificity compared to small molecule inhibitors, while providing a larger area of interaction with PPIs.1, 2 Added to this is the fact that peptide therapeutics also fare better than biologics (therapeutic proteins and antibodies) in terms of reduced immunogenicity, improved production costs as well as the ability to introduce chemical modifications (in synthetic peptides) to better mimic the structural properties in the target PPIs.1, 2 One such example of peptide-based PPI inhibition is presented in the publication by Kim et al., in which they inhibit KITENIN (KAI1 C-terminal interacting tetraspanin) by hindering its homodimerization using a peptide derived from a region in its C-terminus. KITENIN, as the name suggests, was identified as a KAI1-interacting partner in a yeast two-hybrid screen3 and plays a role in KITENIN/ErbB4/Dvl2/c-Jun axis that mediates EGFR-independent EGF signalling.4 It has since been shown to be involved in mediating progression and metastasis in several cancers including colorectal cancer (CRC), glioma, gastric, bladder and head and neck cancer.5, 6 Additionally, it has also been implicated in anti-EGFR resistance in CRC.7 These studies have identified KITENIN as a potential novel target for cancer therapy. In their recent publication focused on CRC, Kim et al. showed that the functional form of KITENIN in the plasma membrane exists as homodimers. They also showed that the homodimer disruption results in KITENIN destabilisation and degradation. To exploit this property, the authors designed a peptide, KITENIN dimerization-interfering peptide (KDIP), derived from region 463–471 of KITENIN and fused to a cell-penetrating peptide, with the aim of reducing KITENIN in CRC through disruption of its homodimers. They used this specific part of the KITENIN sequence after identifying it, through a series of mutagenesis studies, as being the most effective in disrupting KITENIN homodimers. They then showed evidence that treatment with KDIP (and other constructs that disrupt the KITENIN homodimerization) has the functional consequence of interfering with increased cell invasion normally observed upon ectopic overexpression of KITENIN (as demonstrated by the same group in a previous publication).3 For the mechanism of action of KDIP, the authors demonstrated that its administration augments the interaction of KITENIN with RACK1 through the RACK1-interacting motif (RIM), which is important for the degradation of KITENIN through autophagy upon KDIP treatment. They further identified Myosin-X, which interacts with the transmembrane portion of KITENIN, to be responsible for maintaining the stability of the KITENIN homodimer and showed that treatment with KDIP downregulates its expression levels through its proteasomal degradation. This led the authors to postulate that treatment with KDIP disrupts the KITENIN dimers and also leads to degradation of Myosin-X, which further adds to KITENIN dimer destabilisation. This exposes the RIM, otherwise masked in the dimer, leading to KITENIN degradation. Finally, they showed that despite a short half-life of 30.9 min in serum, intravenous administration of KDIP resulted in a significant, dose-dependent reduction of tumour growth in a syngeneic subcutaneous mouse model of KITENIN-overexpressing CT26 cells, but had little effect on non-overexpressing CT26 tumours. Furthermore, intravenous KDIP treatment also reduced liver colonisation by KITENIN-overexpressing CT26 cells in a hepatic metastasis model. Therefore, while shedding light on a novel aspect of KITENIN's biology and how homodimerization regulates its stability, the authors have shown this feature to be a novel actionable target for cancer intervention and designed a first tool, KDIP, to modulate it. Importantly, while in this specific study the authors have focused on the effect of KDIP on CRC, the fact that KITENIN is overexpressed and plays a role in the progression of several cancer types means that the therapeutic benefit of KDIP could potentially extend to these malignancies as well. Additionally, as KITENIN and its downstream signalling have been implicated in anti-EGFR resistance in CRC, combining KDIP with anti-EGFR could be a promising therapeutic strategy to treat anti-EGFR-resistant CRC. While this is the first study showing the therapeutic benefit of targeting KITENIN with a peptide, the feasibility of targeting KITENIN as a potential cancer treatment had already been validated in previous studies using small interfering RNA, micro RNA and small molecules,8-10 thereby reinforcing this principle. Hence, based on these data, KDIP seems to be a promising novel agent for the treatment of KITENIN-overexpressing metastatic CRC and holds the potential to be developed further. Nevertheless, it is important to address certain concerns before considering KDIP to be worthy of clinical development. First and foremost, in this study, the authors have shown the efficacy of KDIP in syngeneic mouse models alone, leaving the question of whether the same effect also applies to human tumours unanswered. Additionally, to show the effect of KDIP on CRC metastasis, the authors make use of the liver colonisation model. This merely demonstrates that KDIP prevents the colonisation of the liver in this specific model and does not address if it could also prevent or treat spontaneous liver metastases, a setting more reflective of the clinical scenario. Furthermore, the authors have not investigated the effect of KDIP on normal tissues, a crucial aspect to rule out any toxicities. Therefore, while KDIP holds promise as novel cancer therapeutic, it is still too early to tell whether it is worth considering its further development into a clinical drug, but we remain hopeful that we will soon be able to learn more about it. The authors declare no conflict of interest.

Cite

APA

Kaur, J., & Soucek, L. (2022). Going for a “KDIP” in colorectal cancer treatment. Clinical and Translational Discovery. https://doi.org/10.1002/ctd2.108

Vancouver

Kaur J, Soucek L. Going for a “KDIP” in colorectal cancer treatment. Clinical and Translational Discovery. 2022. doi:10.1002/ctd2.108

BibTeX
@article{Kaur2022,
  author = {Kaur, Jastrinjan and Soucek, Laura},
  title = {Going for a “KDIP” in colorectal cancer treatment},
  journal = {Clinical and Translational Discovery},
  year = {2022},
  doi = {10.1002/ctd2.108}
}
Start for free →